Detalles de la búsqueda
1.
Efficacy of Naldemedine on Intestinal Hypomotility and Adhesions in Rodent Models of Postoperative Ileus.
Biol Pharm Bull;
46(12): 1714-1719, 2023 Dec 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-37853612
2.
Pharmacological Profile of Naldemedine, a Peripherally Acting µ-Opioid Receptor Antagonist: Comparison with Naloxone and Naloxegol.
J Pharmacol Exp Ther;
373(3): 438-444, 2020 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-32169839
3.
Discovery of naldemedine: A potent and orally available opioid receptor antagonist for treatment of opioid-induced adverse effects.
Bioorg Med Chem Lett;
29(1): 73-77, 2019 01 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-30446313
4.
Pharmacological evaluation of novel (6-aminopyridin-3-yl)(4-(pyridin-2-yl)piperazin-1-yl) methanone derivatives as TRPV4 antagonists for the treatment of pain.
Bioorg Med Chem;
25(7): 2177-2190, 2017 04 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-28284871
5.
Discovery of novel 2',4'-dimethyl-[4,5'-bithiazol]-2-yl amino derivatives as orally bioavailable TRPV4 antagonists for the treatment of pain: Part 2.
Bioorg Med Chem Lett;
26(20): 4936-4941, 2016 10 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-27634196
6.
Discovery of novel 2',4'-dimethyl-[4,5'-bithiazol]-2-yl amino derivatives as orally bioavailable TRPV4 antagonists for the treatment of pain: Part 1.
Bioorg Med Chem Lett;
26(20): 4930-4935, 2016 10 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-27637151
7.
Effect of the norepinephrine transporter (NET) inhibition on µ-opioid receptor (MOR)-induced anti-nociception in a bone cancer pain model.
J Pharmacol Sci;
125(3): 264-73, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-24965165
8.
The contribution of Gi/o protein to opioid antinociception in an oxaliplatin-induced neuropathy rat model.
J Pharmacol Sci;
126(3): 264-73, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-25346041
9.
Establishment of opioid-induced rewarding effects under oxaliplatin- and Paclitaxel-induced neuropathy in rats.
J Pharmacol Sci;
126(1): 47-55, 2014.
Artículo
en Inglés
| MEDLINE | ID: mdl-25141998
10.
Synthesis of quinolinomorphinan-4-ol derivatives as δ opioid receptor agonists.
Bioorg Med Chem;
20(2): 949-61, 2012 Jan 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-22197670
11.
Naldemedine: Peripherally Acting Opioid Receptor Antagonist for Treating Opioid-induced Adverse Effects.
Curr Top Med Chem;
20(31): 2830-2842, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32648846
12.
Preventive effects of naldemedine, peripherally acting µ-opioid receptor antagonist, on morphine-induced nausea and vomiting in ferrets.
Life Sci;
257: 118048, 2020 Sep 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-32622946
13.
The antagonistic activity profile of naloxone in µ-opioid receptor agonist-induced psychological dependence.
Neurosci Lett;
735: 135177, 2020 09 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-32569809
14.
Design and synthesis of novel delta opioid receptor agonists and their pharmacologies.
Bioorg Med Chem Lett;
19(10): 2792-5, 2009 May 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-19362480
15.
Pharmacologic effects of naldemedine, a peripherally acting µ-opioid receptor antagonist, in in vitro and in vivo models of opioid-induced constipation.
Neurogastroenterol Motil;
31(5): e13563, 2019 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-30821019
16.
Sensitization of transient receptor potential vanilloid 4 and increasing its endogenous ligand 5,6-epoxyeicosatrienoic acid in rats with monoiodoacetate-induced osteoarthritis.
Pain;
159(5): 939-947, 2018 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-29438227
17.
Effect of estrogen on morphine- and oxycodone-induced antinociception in a female femur bone cancer pain model.
Eur J Pharmacol;
773: 1-12, 2016 Feb 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-26802873
18.
[Pharmacological profiles of benzodiazepinergic hypnotics and correlations with receptor subtypes].
Nihon Shinkei Seishin Yakurigaku Zasshi;
25(3): 143-51, 2005 Jun.
Artículo
en Japonés
| MEDLINE | ID: mdl-16045197
19.
Morphine and oxycodone, but not fentanyl, exhibit antinociceptive effects mediated by G-protein inwardly rectifying potassium (GIRK) channels in an oxaliplatin-induced neuropathy rat model.
Neurosci Lett;
580: 119-24, 2014 Sep 19.
Artículo
en Inglés
| MEDLINE | ID: mdl-25128218
20.
Structure-activity relationship studies and discovery of a potent transient receptor potential vanilloid (TRPV1) antagonist 4-[3-chloro-5-[(1S)-1,2-dihydroxyethyl]-2-pyridyl]-N-[5-(trifluoromethyl)-2-pyridyl]-3,6-dihydro-2H-pyridine-1-carboxamide (V116517) as a clinical candidate for pain management.
J Med Chem;
57(15): 6781-94, 2014 Aug 14.
Artículo
en Inglés
| MEDLINE | ID: mdl-25057800